CorporateR&D Collaboration
Almirall enters into Integrated Discovery Agreement with Proteros
Barcelona, September 22, 2011. Almirall, S.A. and Proteros biostructures GmbH today announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.
Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to identify and optimize for selectivity and potency small molecule inhibitors of a specific enzyme.
Dr Jorge Beleta, Director Discovery Strategy and Alliances at Almirall remarked “we have worked with and been impressed by Proteros for many years on our structural biology and compound profiling projects and we see this broadening of our relationship to fully integrated projects as an exciting next step.”
Dr Torsten Neuefeind, Chief Executive Officer for Proteros commented ”We are delighted to be selected by Almirall as their partner for this programme. Proteros’s approach of knowledge driven fragment evolution has been validated within different protein classes and we look forward to demonstrating further success within this collaboration.”
About Proteros
Proteros is a privately held company, which provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.
About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.
Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.
For further information please visit the website at: www.almirall.com
Contact:
Proteros biostructures GmbH Almirall
Thomas Waldmann, Ph.D.Sonia Sansegundo/Vito Ballestero
Am Klopferspitz 19 Ketchum Pleon
82152 Martinsried
GermanySpain
Phone: +49 89 7007 61 – 0 Phone: +34 91 788 32 00
Internet: www.proteros.com
Press release